Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
about
Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivoSyntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complexSpecific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardiumRecent insights into the mechanisms of vasospastic anginaSignaling by gasotransmittersNitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and MechanismsTherapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseRNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclaseNitrate/Nitrite as Critical Mediators to Limit Oxidative Injury and InflammationStructure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular DiseasesReview: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionSignaling and stress: The redox landscape in NOS2 biologyContrasting vascular effects caused by loss of Bardet-Biedl syndrome genes.Nitric oxide directly promotes vascular endothelial insulin transport.Nitric oxide is a key component in inflammation-accelerated tumorigenesis.Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea.Biphasic regulation of P-glycoprotein function and expression by NO donors in Caco-2 cells.Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.Inducible nitric oxide synthase deficiency in myeloid cells does not prevent diet-induced insulin resistanceThe fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.Myosin phosphatase target subunit 1 (MYPT1) regulates the contraction and relaxation of vascular smooth muscle and maintains blood pressure.Hydrogen peroxide alters splicing of soluble guanylyl cyclase and selectively modulates expression of splicing regulators in human cancer cells.Protective effect of the methanol extract from Cryptotaenia japonica Hassk. against lipopolysaccharide-induced inflammation in vitro and in vivoAtrial natriuretic peptide frameshift mutation in familial atrial fibrillation.Thymosin Beta-4, Actin-Sequestering Protein Regulates Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Nitric Oxide Production in HeLa Cervical Cancer Cells.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Nitric oxide receptor soluble guanylyl cyclase undergoes splicing regulation in differentiating human embryonic cells.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.S-nitrosylation-regulated GPCR signaling.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesHistone demethylase LSD1 deficiency during high-salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension.Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.Nitric oxide-cyclic GMP signaling in stem cell differentiationHydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels.Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?Capillary Isoelectric Focusing Immunoassay for Fat Cell Differentiation Proteomics.Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
P2860
Q24301869-E7686104-E86E-4930-8D40-F817CFD9C94EQ24308697-CD82B4FB-D7A2-4706-B359-CB64113237B7Q24320079-D566B309-4E05-4968-80D7-4F1C395AA07AQ24651247-512CAB92-01BC-424F-ADA5-E9B92F1439ABQ24654071-F05576F4-74AA-41C6-BCDB-B32B2705AF18Q24656438-BEC5CB12-6EF5-4248-8229-F4220A32A032Q26744567-E659C208-7AAF-42F0-B1E6-5C9F211EB18FQ26827629-3A3BCD97-E235-43A7-AE14-23DBE4619F48Q27001569-7DED030F-A01A-449C-9F7C-C3BCE8F0212EQ27021987-FB09C48B-DE48-4E12-BB20-DE105A4EFE7FQ27661554-B6097C6B-19AF-4BD6-84F9-2E1AB681E260Q28073279-71219741-4A6F-4C2C-87E3-72B5E6CE6AFBQ28394979-7C7904DE-CA5A-43EC-8322-EDC7210493BAQ28833738-B8CE4C9F-38CB-4F8D-AB37-2B38C2245FF5Q29347284-BBD1DC9A-3BCA-40F3-B7C9-BB392733C0CDQ30409239-31D5394A-E31C-447B-88BB-77515C070ADCQ30438755-3D2D0FF8-2852-4355-A29B-E5FA73AA32B9Q30440623-81AEB387-B9CD-49EE-9AC8-410666A8C1CAQ33567500-D2A93AAE-3877-4C11-AE29-BA354E237785Q33727318-422DC248-175B-4516-8905-D4573CEA8E91Q33917152-54256CBB-445E-482A-8504-45A88CA0ED20Q33993681-E9F9ACAF-0BF6-42E3-BC66-C1DF246B9A65Q34042836-9807588C-A51F-439B-8784-8F7B59F282F1Q34070511-30E4C645-C2F7-4528-8D1F-DFC34D5023BBQ34387675-5A397B08-A87D-470C-A195-D8D65EA1D259Q34461374-4758D5EE-1395-41E2-83A9-DAC777BFA1ABQ34593998-AC74EC54-5E2C-4B82-9A35-2E32380C84C3Q34865055-5649A96D-0A3A-4F92-A4A6-8CD33A1DA5F2Q35010064-75BEC3A2-84A3-486C-96FC-196538AD62C2Q35064619-874B9438-9659-46B6-871F-1532C583037EQ35075847-D76CB1E6-5002-4FE2-851E-6AFCC99210FAQ35091511-D28C22F8-F6E3-4C73-9BF1-39CCF8475B01Q35156618-C736B194-0358-4DB4-9F4B-14C2608B3646Q35543481-26BBA8F2-6618-43BA-9CC7-A51D3ACB440AQ35558572-AFE9E017-6085-41E4-BEB1-EC704E6C5431Q35596709-E46C3878-81F7-491E-A365-9351DCC5E333Q35603720-6258914C-3D51-4923-AB19-D63D89764217Q35640718-E4FDB818-CA84-41B8-8E5B-57A2070D8FA9Q35679898-35E7AB05-ED9E-4EF5-B198-7570733F36B7Q35768993-992FE6AB-D0FC-426E-B8D7-23DACF3CDDF7
P2860
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@ast
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@en
type
label
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@ast
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@en
prefLabel
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@ast
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@en
P356
P1476
Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.
@en
P304
P356
10.1056/NEJMSA063904
P407
P50
P577
2006-11-01T00:00:00Z